combretastatin has been researched along with Angiogenesis, Pathologic in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 17 (58.62) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Elming, PB; Horsman, MR; Nielsen, PS; Wittenborn, TR | 1 |
| Aoshima, K; Hoshino, Y; Izumi, Y; Takagi, S | 1 |
| Sherbet, GV | 1 |
| Horsman, MR | 1 |
| Bertelsen, LB; Busk, M; Bussink, J; Horsman, MR; Iversen, AB; Laustsen, C; Lok, J; Munk, OL; Nielsen, T; Stødkilde-Jørgensen, H; Wittenborn, TR | 1 |
| Izumi, Y; Takagi, S | 1 |
| Azzariti, A; Gnoni, A; Numico, G; Paradiso, A; Porcelli, L; Quatrale, AE | 1 |
| Bertelsen, LB; Bohn, AB; Brems-Eskildsen, AS; Horsman, MR; Laurberg, T; Møller, BK; Nielsen, T; Stødkilde-Jørgensen, H; Wittenborn, T | 1 |
| Chen, Z; Deng, C; Feng, L; Li, C; Long, Y; Su, T; Zhang, X | 1 |
| Abma, E; Daminet, S; de Rooster, H; Ni, Y; Smets, P | 1 |
| Basso, G; Bortolozzi, R; Mitola, S; Porcù, E; Primac, I; Ravelli, C; Romagnoli, R; Ronca, R; Salvador, A; Vedaldi, D; Viola, G | 1 |
| Bueno, O; Canela, MD; Liekens, S; Martins, MS; Pérez-Pérez, MJ; Priego, EM | 1 |
| Gevertz, JL | 1 |
| Burchill, SA; Dalal, S | 1 |
| Kanthou, C; Tozer, GM | 1 |
| Cai, YC; Xian, LJ; Zou, Y | 1 |
| Haselwandter, CA; Kardar, M; Kohandel, M; Sengupta, S; Sivaloganathan, S | 1 |
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
| Barsoum, J; Borella, C; Foley, KP; Jiang, J; Korbut, T; Li, H; Sang, J; Sonderfan, AJ; Wu, Y; Ye, J; Zhang, M; Zhang, X; Zhou, D | 1 |
| Gore, M; Gourley, C; Hall, M; Jayson, G; Kaye, S; Ledermann, J; McNeish, I; Perren, T; Rustin, G | 1 |
| Mariani, SM | 1 |
| Kiziltepe, T; Sasisekharan, R; Sengupta, S | 1 |
| Baguley, BC; Kanthou, C; Tozer, GM | 1 |
| Mooney, D | 1 |
| Capila, I; Eavarone, D; Kiziltepe, T; Sasisekharan, R; Sengupta, S; Watson, N; Zhao, G | 1 |
| Bajenaru, ML; Feuer, W; Fini, ME; Jockovich, ME; Murray, TG; Piña, Y; Suarez, F | 1 |
| Randal, J | 1 |
| Bailly, C; Lansiaux, A; Verdier-Pinard, P | 1 |
| Hill, SA; Kanthou, C; Parkins, CS; Tozer, GM | 1 |
9 review(s) available for combretastatin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Suppression of angiogenesis and tumour progression by combretastatin and derivatives.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Cell Movement; Cell Proliferation; Disease Progression; Epithelial-Mesenchymal Transition; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Signal Transduction; Tumor Burden | 2017 |
New vascular disrupting agents in upper gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Diphosphates; Gastrointestinal Neoplasms; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Serine; Stilbenes; Upper Gastrointestinal Tract | 2014 |
Combretastatin A4-phosphate and its potential in veterinary oncology: a review.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Dog Diseases; Dogs; Humans; Medical Oncology; Mice; Neoplasms; Neovascularization, Pathologic; Veterinary Medicine | 2017 |
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Drug Resistance, Neoplasm; Humans; Neoplasms; Neovascularization, Pathologic; Tubulin Modulators | 2009 |
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones | 2010 |
Targeted anti-vascular therapies for ovarian cancer: current evidence.
Topics: Angiogenesis Inhibitors; Angiopoietins; Angiostatins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bibenzyls; Female; Fibroblast Growth Factors; Flavonoids; Humans; Molecular Targeted Therapy; Neovascularization, Pathologic; Ovarian Neoplasms; Thrombospondins; Treatment Outcome; Vascular Endothelial Growth Factors | 2013 |
Disrupting tumour blood vessels.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Capillary Permeability; Clinical Trials as Topic; Endothelial Cells; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes; Xanthones | 2005 |
[Combretastatin A4 phosphate].
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Quantitative Structure-Activity Relationship; Rats; Stilbenes; Transplantation, Heterologous | 2001 |
The biology of the combretastatins as tumour vascular targeting agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Endothelium, Vascular; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes | 2002 |
20 other study(ies) available for combretastatin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bibenzyls; CTLA-4 Antigen; Diphosphates; Disease Progression; Drug Resistance, Neoplasm; Female; Immune Checkpoint Inhibitors; Male; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Stilbenes; Treatment Outcome | 2020 |
Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells.
Topics: Animals; Bibenzyls; Cells, Cultured; Dogs; Endothelial Cells; Endothelium, Vascular; Humans; Neoplasms; Neovascularization, Pathologic; Phosphates; Stilbenes | 2017 |
Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Female; Gamma Rays; Lung; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Radiation-Sensitizing Agents; Skin; Urinary Bladder | 2017 |
The potential of hyperpolarized
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Carbon Isotopes; Female; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Positron-Emission Tomography; Tissue Distribution | 2017 |
Vascular disrupting effect of combretastatin A-4 phosphate with inhibition of vascular endothelial cadherin in canine osteosarcoma-xenografted mice.
Topics: Animals; Antigens, CD; Bibenzyls; Cadherins; Dog Diseases; Dogs; Endothelium, Vascular; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Osteosarcoma | 2019 |
A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models.
Topics: Animals; Bibenzyls; Carcinoma, Squamous Cell; Disease Models, Animal; Female; Flow Cytometry; Granulocytes; Humans; Mammary Neoplasms, Animal; Mice; Necrosis; Neovascularization, Pathologic; Neutrophils | 2014 |
Construction of a two-in-one liposomal system (TWOLips) for tumor-targeted combination therapy.
Topics: Animals; Antineoplastic Agents; Bibenzyls; Doxorubicin; Drug Combinations; Drug Delivery Systems; Drug Stability; Drug Storage; Female; Humans; Liposomes; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Particle Size; Silicon Dioxide; Survival Rate; Xenograft Model Antitumor Assays | 2014 |
Vascular disrupting activity of combretastatin analogues.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antigens, CD; Bibenzyls; Cadherins; Capillary Permeability; Cardiac Myosins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Focal Adhesion Kinase 1; Human Umbilical Vein Endothelial Cells; Humans; Melanoma, Experimental; Mice, Inbred C57BL; Myosin Light Chains; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Signal Transduction; Time Factors | 2016 |
Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Drug Discovery; Hemodynamics; Humans; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Tubulin; Tubulin Modulators | 2016 |
Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Topics: Angiogenesis Inhibitors; Bevacizumab; Bibenzyls; Computer Simulation; Cytotoxins; Drug Combinations; Drug Dosage Calculations; Endothelial Cells; Everolimus; Humans; Models, Statistical; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment; Xanthones | 2016 |
Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bibenzyls; Bone Neoplasms; Cell Proliferation; Diphosphates; Disease Models, Animal; Doxorubicin; Drug Evaluation, Preclinical; Mice; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Sarcoma, Ewing; Stilbenes | 2009 |
Quantitative model for efficient temporal targeting of tumor cells and neovasculature.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Biological Availability; Carcinoma, Lewis Lung; Computer Simulation; Doxorubicin; Drug Delivery Systems; Drug Synergism; Liposomes; Melanoma, Experimental; Mice; Models, Biological; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Time Factors; Treatment Outcome | 2011 |
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |
The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Survival; Dogs; Female; Heart; Hemodynamics; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Microcirculation; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Rabbits; Regional Blood Flow; Tubulin Modulators; Xenograft Model Antitumor Assays | 2012 |
Anti-angiogenesis: the challenges ahead.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Bibenzyls; Biological Availability; Biomarkers; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Endostatins; Endothelial Growth Factors; Endothelium, Vascular; Growth Inhibitors; Humans; Kidney Neoplasms; Microtubules; Neoplasms; Neovascularization, Pathologic; Ontario; Receptors, Vascular Endothelial Growth Factor; Stilbenes | 2003 |
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Cancer: one step at a time.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Humans; Mice; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Stilbenes; Time Factors | 2005 |
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Carcinoma, Lewis Lung; Coculture Techniques; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Endothelial Cells; Humans; Melanoma, Experimental; Mice; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Stilbenes; Time Factors; Tissue Distribution | 2005 |
Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model.
Topics: Actins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Biomarkers, Tumor; Cell Proliferation; Disease Models, Animal; Endoglin; Endothelium, Vascular; Intracellular Signaling Peptides and Proteins; Ki-67 Antigen; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neovascularization, Pathologic; Pericytes; Pregnadienediols; Retinal Neoplasms; Retinoblastoma; Stilbenes | 2007 |
Antiangiogenesis drugs target specific cancers, mechanisms.
Topics: Angiostatins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Humans; Matrix Metalloproteinase Inhibitors; Neoplasms; Neovascularization, Pathologic; Peptide Fragments; Plasminogen; Stilbenes | 2000 |